• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Enovis Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/8/25 6:19:47 AM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email
    cfx-20250508
    false00014208002025-05-08May 8, 202500014208002025-05-082025-05-08

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

     Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 8, 2025
     
    Enovis Corporation
    (Exact name of registrant as specified in its charter)
     
    Delaware001-3404554-1887631
    (State or other jurisdiction(Commission(I.R.S. Employer
    of incorporation)File Number)Identification No.)

     2711 Centerville Road, Suite 400
    Wilmington, DE 19808
    (Address of Principal Executive Offices) (Zip Code)
     
    (302) 252-9160
    (Registrant's telephone number, including area code)


    (Former name, former address and former fiscal year, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, par value $0.001 per shareENOVNew York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02. Results of Operations and Financial Condition.

    On May 8, 2025, the Company issued a press release reporting financial results for the first quarter ended April 4, 2025. A copy of the Company's press release is attached to this report as Exhibit 99.1 and is incorporated into Item 2.02 of this report by reference. The Company has scheduled a conference call for 8:30 a.m. Eastern on May 8, 2025 to discuss its financial results.






    Item 9.01. Financial Statements and Exhibits.

    (d)    Exhibits

    99.1 Enovis Corporation press release dated May 8, 2025, reporting financial results for the first quarter ended April 4, 2025.

    104 Cover Page Interactive Data File - The cover page from this Current Report on Form 8-K is formatted in Inline XBRL



    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Date:May 8, 2025
     Enovis Corporation
    By:/s/ John Kleckner
    Name: John Kleckner
    Title:Vice President
    Controller and Chief Accounting Officer
    (Principal Accounting Officer)

    Get the next $ENOV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    12/15/2023$62.00 → $70.00Buy
    Needham
    10/20/2023$75.00Buy
    ROTH MKM
    6/26/2023$70.00Buy
    Needham
    More analyst ratings

    $ENOV
    SEC Filings

    See more
    • SEC Form SD filed by Enovis Corporation

      SD - Enovis CORP (0001420800) (Filer)

      5/30/25 4:05:37 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form 8-K filed by Enovis Corporation

      8-K - Enovis CORP (0001420800) (Filer)

      5/21/25 4:07:27 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Enovis Corporation

      10-Q - Enovis CORP (0001420800) (Filer)

      5/8/25 5:14:27 PM ET
      $ENOV
      Industrial Specialties
      Health Care